This year, Europe’s most important and most valuable biotech prize, the European BioTechnica Award, will be confered either to Amaxa GmbH, Intercell AG or Genmab A/S. These three companies have been chosen from an international pool of 16 companies which submitted the comprehensive application form. The winner will be announced at a high-class event in Zurich.
Amaxa, Genmab and Intercell are the finalists for the fourth European BioTechnica Award presented by the Deutsche Messe AG (Hannover, Germany). The BioTechnica Award jury will confer the prize at a festive event on October, 12 in the Park Hyatt Hotel in Zurich. “With the prize award ceremony, talks by guest speakers and an informal get-together for all participants, the event creates the perfect business platform for biotech professionals to network and make valuable contacts,“ says Stephan Kühne, member of the board of Deutsche Messe AG. The winner receives a prize to the value of 40,000 euros. Judging criteria are scientific innovation, commercial viability, market relevance, marketing concept and business model. The 2006 jury consists of a number of well-known industry insiders among them Prof. Dr. Peter Stadler (Managing director Artemis Pharmaceuticals GmbH), Dr. Luca Benatti (CEO Newron Pharmaceuticals SPA), Dr. Philippe Pouletty (Honory Chairman France Biotech) and Dr. Karsten Henco (founder Evotec AG and Qiagen NV).
Talks by distinguished speakers will set the scene for the festive ceremony. “The keynote addresses are sure to stimulate plenty of lively debate at the informal get-together afterwards,” Kühne predicts. The line-up consists of Dr. Annette Schavan (German minister of Education and Research), Dr. Peter Hug (Roche’s Global Head of Pharma Partnering), Jörn Aldag (CEO Evotec AG) and Dr. Hans-Jürgen Leuchs (Board Member Boehringer Ingelheim). The award ceremony follows the Biotech CEO Conference hosted by the German Stock Exchange and DZ BANK AG in Zurich.
Former winners of the price are GPC Biotech AG, Prionics AG and MediGene AG. The European BioTechnica Award is confered every year by the Deutsche Messe AG and a group of partners, among them BIOCOM AG, the publishing house of EuroBiotechNews.
The company: Amaxa currently employs a workforce of 145 and generated revenues of 16.6 million Euros in 2005. In addition to its headquarters in Cologne/Germany, the company, which was founded in 1998, also operates a facility in Gaithersburg/USA.
The business: Amaxa develops and sells transfection products in the field of non-viral gene-transfer for primary cells and cell lines. The patented Nucleofactor technology is an ex-vivo tool for gene-based medicine. Technologies under development are also suitable for in-vivo gene transfer.
The Management: Rainer Christine (Managing Director), Alexander Müller (Financial Director), Dr. Hans-Günter Brünker (Corp. Development), Wolfgang Kintzel (Marketing & Sales), Dr. Titus Kretzschmar (R&D).
The company: Genmab currently employs a workforce of 220 and generated revenues of 13.2 million euros in 2005. Genmab runs several operations in Europe and the United States and is listed at the Copenhagen Stock Exchange.
The business: Genmab develops human antibodies for the treatment of cancer, infectious diseases and rheumatoid arthritis and runs six clinical programs. The company has closed several alliances with partners, among them Amgen, Serono and Roche. In 1998 Genmab was spun-off from Medarex Inc. to commercialize the UltiMAb® platform.
The Management: Lisa Drakeman (CEO), Claus Juan Møller-San Pedro (COO), Bo Kruse (CFO), Annarie Lyles (Business development), Jan van de Winkel (CSO).
The company: Intercell employs a workforce of 160 and generated revenues of 8.5 million euros in 2005. The company, founded in 1998, runs an in-house GMP-facility in Livingston/Scotland, in addition to its headquarters in Vienna. In early 2005, Intercell listed at the Vienna stock exchange and was the best performing biotech IPO in Europe.
The business: Intercell develops antigens and immunizers (adjuvants), which are derived from its proprietary technology platforms. Novartis recently bought a 6.1% stake in Intercell and received the co-commercialization rights for the company‘s lead product, a Japanese Encephalitis vaccine in phase III.
The Management: Gerd Zettlmeissl (CEO), Alexander von Gabain (CSO), Werner Lanthaler (CFO)